jats:titleAbstract</jats:title>jats:secjats:titlePurpose of Review</jats:title>jats:pPeople with cystic fibrosis (CF) suffer chronic lung infections with a range of antimicrobial-resistant bacterial pathogens. There is an urgent need for researchers to develop novel anti-infectives to treat these problematic infections, but how can we select bacterial strains which are relevant for robust testing and comparative research?</jats:p></jats:sec>jats:secjats:titleRecent Findings</jats:title>jats:pjats:italicPseudomonas aeruginosa</jats:italic>,jats:italicBurkholderia cepacia</jats:italic>complex andjats:italicBurkholderia gladioli</jats:italic>,jats:italicMycobacterium abscessus</jats:italic>complex,jats:italicStaphylococcus aureus, Haemophilus influenza,</jats:italic>and several multidrug-resistant Gram-negative species were selected as key CF infections that urgently require new therapeutics. Reference isolates and strain panels were identified, and a summary of the known genotypic diversity of each pathogen was provided.</jats:p></jats:sec>jats:secjats:titleSummary</jats:title>jats:pHere, we summarise the current strain resources available for priority CF bacterial pathogens and highlight systematic selection criteria that researchers can use to select strains for use in therapeutic testing.</jats:p></jats:sec>